Advertisement

European Journal of Dermatology

, Volume 24, Issue 3, pp 293–296 | Cite as

Recurrent angioedema: diagnosis strategy and biological aspects

  • Laurence Bouillet
  • Isabelle Boccon-Gibod
  • Frédéric Berard
  • Jean-François Nicolas
Review article
  • 53 Downloads

Abstract

The aetiologies of recurrent angioedema (AE) comprise the frequent histaminergic AE and the rare bradykinin-mediated AE. Diagnosis must be done carefully because they do not have the same treatment. Diagnosis strategy is clinical. The most specific symptoms for bradykinin AE are: isolated AE without wheals, long duration of the attack, abdominal localisation. The unique useful biological tests for the diagnosis of bradykinin AE are C1Inh exploration which is altered in hereditary AE (HAE) types I and II. No other biological test is useful in clinical practice at present. In case of suspicion of bradykinin AE with normal C1Inh, physicians must think of drug-induced AE. Hereditary AE with normal C1Inh may be associated with a mutation on gene F12 in 20% of cases. For 80% of patients without mutation, the diagnosis must be done very carefully.

Keywords

angioedema urticaria histamine bradykinin C1Inh diagnosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144: 708–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Kaplan AP, Greavs MW. Angioedema. J Am Acad Dermatol 2005; 53: 373–88.PubMedCrossRefGoogle Scholar
  3. 3.
    Zingale L, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175: 1065–70.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Kulthanan K, Jiamton S, Boochangkool K, Jongjarearnprasert K. Angioedema: Clinical and Etiological Aspects. Clin Dev Immunol 2007; 2007: 26438.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Bouillet L, Boccon-Gibod I, Massot C. Bradykinin mediated angioedema. Rev Med Intern 2011; 32: 225–31.CrossRefGoogle Scholar
  6. 6.
    Boccon-Gibod I. Urticaire/angioedème histaminique ou bradykinique. Rev Fr Allergol 2012; 52: 327–32.CrossRefGoogle Scholar
  7. 7.
    Longhurst H, Cicardi M. Hereditary angioedema. Lancet 2012; 379: 474–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Augey F, Nosbaum A, Berard F, Nicolas JF. Corticosteroids should not be used in urticaria because of the potential risk of steroid dependence and development of severe anti-H1-resistant urticaria. Eur J Dermatol. 2011; 21: 431.PubMedGoogle Scholar
  9. 9.
    Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Bork K, Meng G, Staubach P, Hardt J. Hereditary Angioedema: New Findings concerning Symptoms, Affected Organs, and Course. Am J Med 2006; 119: 267–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24: 599–606.PubMedCrossRefGoogle Scholar
  12. 12.
    Beltrami L, Zanichelli A, Zingale L, Vacchinib R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29: 2273–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Consensus HAS urticaire chronique 2003: http://www.hassante.fr/portail/upload/docs/application/pdf/urticaire_court.pdfGoogle Scholar
  14. 14.
    Cugno M, Nussberger J, Cicardi M, Agostini A. Bradykinin and the physiopathology of angioedema. Int Imunopharmacol 2003; 3: 311–7.CrossRefGoogle Scholar
  15. 15.
    Vitrat-Hincky V, Gompel A, Dumestre-Perard C, et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010; 65: 1331–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24–37.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Longhurst H, Cicardi M. Hereditary angio-oedema Lancet 2012; 379: 474–81.Google Scholar
  18. 18.
    Gordon EM, Ratnoff OD, Saito H, Donaldson VH, Pensky J, Jones PK. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med 1980; 96: 762–9.PubMedGoogle Scholar
  19. 19.
    Cohen A, Laskin C, Tarlo S. C1 esterase inhibitor in pregnancy. J Allergy Clin Immunol 1992; 90: 412–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008; 8: 156–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Simons FE, Ardusso LR, Bilò MB, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012; 12: 389–99.PubMedCrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2014

Authors and Affiliations

  • Laurence Bouillet
    • 1
    • 2
  • Isabelle Boccon-Gibod
    • 1
  • Frédéric Berard
    • 3
  • Jean-François Nicolas
    • 3
  1. 1.National Reference Centre for Angioedema (CREAK), Internal medicine departmentGrenoble University HospitalGrenoble cedex 09France
  2. 2.Unité Inserm 1036, CEAUniversité de médecine Joseph-FourierGrenobleFrance
  3. 3.Immunology and Allergy Clinic, Inserm U1111-CIRIUniversité Lyon1Pierre-BéniteFrance

Personalised recommendations